Clemedi AG

The current diagnosis of anti-microbial resistant infections is largely based on culturing bacteria in the presence of various antibiotics. This is both labor and time-consuming, leading to sub-optimal therapy and an increase in morbidity and mortality of the patient. We combine novel technologies - next-generation sequencing and machine learning, which will bring a quantum leap into how we diagnose infections and enable us to achieve targetted therapy instead.